Induction interferon therapy in naïve patients with chronic hepatitis C: Increased end-of-treatment virological responses but absence of long-term benefit

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 4, 2001, Pages 551-557

  Hadziyannis, A S ^a   Papaioannou, C ^a   Spanou, F ^a   Manesis, E K ^a   Hadziyannis, S J ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; INTERFERON INDUCTION; KINETICS; LIVER DISEASE; LONG TERM CARE; MALE; PRIORITY JOURNAL; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035073018     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00946.x     Document Type: Article

References (31)

1. Epidemiology of hepatitis C
2. Natural history of hepatitis C
3. Hepatitis C virus in Greece and its role in chronic liver disease and hepatocellular carcinoma
4. Therapy of hepatitis C. Meta-analysis of interferon alfa-2b trials
5. Interferon alfa-2b for chronic hepatitis C. effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial
6. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients
7. Management of hepatitis C
8. Treatment of chronic hepatitis C with α-interferon: An analysis of the literature
9. Meta-analysis of interferon randomized trials in the treatment for chronic hepatitis C: Effects of dose and duration
10. Usefulness of interferon for treatment of hepatitis C
11. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
12. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
13. Randomised trial of interferon α 2b plus ribavirin for 48 weeks for treatment of chronic infection with hepatitis C virus
14. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
15. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
16. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
17. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
18. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover
19. Effective administration methods and dosages of interferon therapy for chronic hepatitis C
20. Efficacy and side effects of intermittent recombinant interferon-alpha 2a in chronic aggressive hepatitis C: With or without initial daily administration
21. Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: Results of a multicenter randomized controlled dose study
22. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group
23. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C
24. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load
25. The effects of a high dose, short course of interferon on hepatitis C
26. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: A multicenter randomized trial
27. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: A multicenter randomised trial. Multicenter GER-CYT-04 Group
28. Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C
29. Histological grading and staging of chronic hepatitis
30. Induction dosing with interferon α 2b: An international study
31. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C